Voting Rights and Shares Capital of the Company

Why It Matters

The data clarifies shareholder voting capacity, informing potential investors and ensuring compliance with French market transparency rules. It also signals that Nanobiotix’s equity base remains stable, reducing dilution risk.

Key Takeaways

• Shares outstanding: 48.45 million as of Jan 31 2026
• Theoretical voting rights total 50.15 million
• Exercisable voting rights slightly lower at 50.13 million
• No new share issuance reported in this filing
• Disclosure meets French AMF reporting requirements

Pulse Analysis

Nanobiotix SA, a Paris‑based late‑stage biotech firm, continues to attract attention for its physics‑driven cancer therapeutics and nanotechnology platforms. Listed on Euronext Paris and Nasdaq, the company’s growth narrative hinges on robust R&D pipelines and a portfolio of over 25 patent families. Regular capital disclosures, such as the recent voting‑rights filing, reinforce market confidence by providing transparent insight into the equity structure that underpins shareholder value and corporate governance.

The February 17 filing reveals 48.45 million shares outstanding, translating into 50.15 million theoretical voting rights and 50.13 million exercisable rights. The slight gap reflects shares held in treasury where voting is suspended, a standard adjustment under French AMF rules. These figures are critical for investors monitoring control thresholds, as any acquisition or proxy contest would need to surpass specific voting‑right percentages. Maintaining a stable voting‑right base also suggests the company has not pursued recent equity financing that could dilute existing shareholders.

From a regulatory perspective, the disclosure satisfies article L.233‑8 II of the French Commercial Code and AMF regulation 223‑16, which mandate public companies to publish up‑to‑date capital and voting‑right data. Such compliance not only avoids penalties but also signals disciplined corporate governance to institutional investors. As Nanobiotix advances its clinical programs, the unchanged capital structure may be viewed as a positive sign, indicating that the firm is financing development primarily through existing resources and strategic partnerships rather than equity dilution, thereby preserving shareholder value.